Sorin Group
Sorin hopes Perceval valve will rescue flat results
U.S. regulators OK $1.4B Sorin-Cyberonics tie-up
J&J deals Cordis for nearly $2B | The week in medtech M&A
UPDATE: Cyberonics to buy Italy’s Sorin for $1.4B
Regulators deal WMGI double whammy | Regulatory news for the week of February 9, 2015
FDA awards priority review status to Cohera Medical’s surgical sealant Sylys | Regulatory news for the week of December 22, 2014
Sorin drops $20m on stake in Respicardia
Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.
Sorin announces first U.S. implant of Solo Smart heart valve
Sorin Group (BIT:SRN) said that a patient in Indianapolis was the first U.S. recipient of its recently approved Solo Smart aortic heart valve.
Press Release: Sorin Group announces CE Mark approval for Crown PRT heart valve
Milan, Italy – Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today it has been granted CE mark certification for its innovative stented aortic bioprosthesis Crown PRT, now commercially available in Europe.
Sorin touts E.U. approval for next-gen heart valve
Sorin Group (BIT:SRN) announced this week that it landed European CE Mark approval for its latest aortic heart valve, the Crown PRT.